Literature DB >> 23727942

Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period.

Fred Kyeyune, Immaculate Nankya, Samar Metha, Juliet Akao, Emmanuel Ndashimye, Denis M Tebit, Benigno Rodriguez, Cissy Kityo, Robert A Salata, Peter Mugyenyi, Eric Arts.   

Abstract

OBJECTIVES: To determine the impact of HIV-1 subtype on treatment outcomes and the emergence of drug resistance in the resource limited setting of Kampala, Uganda.
DESIGN: The Joint Clinical Research Centre (JCRC) in Kampala, Uganda has provided over 2000 drug-resistant genotypes (DRGs) over the past 10 years as standard of care for patients failing therapy and 1403 from treatment-naive and experienced patients over the past 10 years have been analyzed for this study.
METHOD: Viral loads, CD4 cell count, treatment histories and other relevant clinical data was compared with the infecting HIV-1 subtype and DRGs of Ugandan patients failing treatment.
RESULTS: Patients failing HAART with DRGs (n = 937) were more frequently infected with subtype D than expected on the basis of the subtype distribution in the treatment-naive population (n = 655) in Kampala (P < 0.001). Higher proportions of treatment failures among subtype D-infected patients were driven by resistance to nucleoside reverse transcriptase inhibitors (NRTI) (P < 0.0002) more than to non-NRTIs (P > 0.04) or protease inhibitors.
CONCLUSION: Higher rates of treatment failure among subtype D as compared with subtype A-infected Ugandans was analogous to the faster disease progression in subtype D-infected patients. The mechanism(s) by which drug resistance may emerge faster in subtype D HIV-1 may relate to higher replicative fitness and increased propensity for a CXCR4 tropism.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23727942      PMCID: PMC4494684          DOI: 10.1097/QAD.0b013e3283610ec7

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  43 in total

1.  In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants.

Authors:  Maria Dolores Iglesias-Ussel; Concepción Casado; Eloísa Yuste; Isabel Olivares; Cecilio López-Galíndez
Journal:  J Gen Virol       Date:  2002-01       Impact factor: 3.891

2.  Relationship between HIV-1 Env subtypes A and D and disease progression in a rural Ugandan cohort.

Authors:  P Kaleebu; A Ross; D Morgan; D Yirrell; J Oram; A Rutebemberwa; F Lyagoba; L Hamilton; B Biryahwaho; J Whitworth
Journal:  AIDS       Date:  2001-02-16       Impact factor: 4.177

3.  New WHO HIV treatment and prevention guidelines.

Authors:  Siobhan Crowley; Nigel Rollins; Nathan Shaffer; Teguest Guerma; Marco Vitoria; Ying-ru Lo
Journal:  Lancet       Date:  2009-11-30       Impact factor: 79.321

4.  HIV-1 drug resistance in antiretroviral-naive patients in sub-Saharan Africa.

Authors:  Raph L Hamers; Kim Ce Sigaloff; Cissy Kityo; Peter Mugyenyi; Tobias F Rinke de Wit
Journal:  Lancet Infect Dis       Date:  2013-03       Impact factor: 25.071

5.  HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study.

Authors:  Raph L Hamers; Carole L Wallis; Cissy Kityo; Margaret Siwale; Kishor Mandaliya; Francesca Conradie; Mariette E Botes; Maureen Wellington; Akin Osibogun; Kim C E Sigaloff; Immaculate Nankya; Rob Schuurman; Ferdinand W Wit; Wendy S Stevens; Michèle van Vugt; Tobias F Rinke de Wit
Journal:  Lancet Infect Dis       Date:  2011-07-27       Impact factor: 25.071

6.  HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads.

Authors:  Jared M Baeten; Bhavna Chohan; Ludo Lavreys; Vrasha Chohan; R Scott McClelland; Laura Certain; Kishorchandra Mandaliya; Walter Jaoko; Julie Overbaugh
Journal:  J Infect Dis       Date:  2007-03-02       Impact factor: 5.226

7.  Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings.

Authors:  Thomas B Campbell; Laura M Smeaton; N Kumarasamy; Timothy Flanigan; Karin L Klingman; Cynthia Firnhaber; Beatriz Grinsztejn; Mina C Hosseinipour; Johnstone Kumwenda; Umesh Lalloo; Cynthia Riviere; Jorge Sanchez; Marineide Melo; Khuanchai Supparatpinyo; Srikanth Tripathy; Ana I Martinez; Apsara Nair; Ann Walawander; Laura Moran; Yun Chen; Wendy Snowden; James F Rooney; Jonathan Uy; Robert T Schooley; Victor De Gruttola; James Gita Hakim
Journal:  PLoS Med       Date:  2012-08-14       Impact factor: 11.069

8.  Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics.

Authors:  Kara G Lassen; Michael A Lobritz; Justin R Bailey; Samantha Johnston; Sandra Nguyen; Benhur Lee; Tom Chou; Robert F Siliciano; Martin Markowitz; Eric J Arts
Journal:  PLoS Pathog       Date:  2009-04-10       Impact factor: 6.823

9.  Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.

Authors:  P Mugyenyi; A S Walker; J Hakim; P Munderi; D M Gibb; C Kityo; A Reid; H Grosskurth; J H Darbyshire; F Ssali; D Bray; E Katabira; A G Babiker; C F Gilks; H Grosskurth; P Munderi; G Kabuye; D Nsibambi; R Kasirye; E Zalwango; M Nakazibwe; B Kikaire; G Nassuna; R Massa; K Fadhiru; M Namyalo; A Zalwango; L Generous; P Khauka; N Rutikarayo; W Nakahima; A Mugisha; J Todd; J Levin; S Muyingo; A Ruberantwari; P Kaleebu; D Yirrell; N Ndembi; F Lyagoba; P Hughes; M Aber; A Medina Lara; S Foster; J Amurwon; B Nyanzi Wakholi; J Whitworth; K Wangati; B Amuron; D Kajungu; J Nakiyingi; W Omony; K Fadhiru; D Nsibambi; P Khauka; P Mugyenyi; C Kityo; F Ssali; D Tumukunde; T Otim; J Kabanda; H Musana; J Akao; H Kyomugisha; A Byamukama; J Sabiiti; J Komugyena; P Wavamunno; S Mukiibi; A Drasiku; R Byaruhanga; O Labeja; P Katundu; S Tugume; P Awio; A Namazzi; G T Bakeinyaga; H Katabira; D Abaine; J Tukamushaba; W Anywar; W Ojiambo; E Angweng; S Murungi; W Haguma; S Atwiine; J Kigozi; L Namale; A Mukose; G Mulindwa; D Atwiine; A Muhwezi; E Nimwesiga; G Barungi; J Takubwa; S Murungi; D Mwebesa; G Kagina; M Mulindwa; F Ahimbisibwe; P Mwesigwa; S Akuma; C Zawedde; D Nyiraguhirwa; C Tumusiime; L Bagaya; W Namara; J Kigozi; J Karungi; R Kankunda; R Enzama; A Latif; J Hakim; V Robertson; A Reid; E Chidziva; R Bulaya-Tembo; G Musoro; F Taziwa; C Chimbetete; L Chakonza; A Mawora; C Muvirimi; G Tinago; P Svovanapasis; M Simango; O Chirema; J Machingura; S Mutsai; M Phiri; T Bafana; M Chirara; L Muchabaiwa; M Muzambi; J Mutowo; T Chivhunga; E Chigwedere; M Pascoe; C Warambwa; E Zengeza; F Mapinge; S Makota; A Jamu; N Ngorima; H Chirairo; S Chitsungo; J Chimanzi; C Maweni; R Warara; M Matongo; S Mudzingwa; M Jangano; K Moyo; L Vere; N Mdege; I Machingura; E Katabira; A Ronald; A Kambungu; F Lutwama; I Mambule; A Nanfuka; J Walusimbi; E Nabankema; R Nalumenya; T Namuli; R Kulume; I Namata; L Nyachwo; A Florence; A Kusiima; E Lubwama; R Nairuba; F Oketta; E Buluma; R Waita; H Ojiambo; F Sadik; J Wanyama; P Nabongo; J Oyugi; F Sematala; A Muganzi; C Twijukye; H Byakwaga; R Ochai; D Muhweezi; A Coutinho; B Etukoit; C Gilks; K Boocock; C Puddephatt; C Grundy; J Bohannon; D Winogron; D M Gibb; A Burke; D Bray; A Babiker; A S Walker; H Wilkes; M Rauchenberger; S Sheehan; C Spencer-Drake; K Taylor; M Spyer; A Ferrier; B Naidoo; D Dunn; R Goodall; J H Darbyshire; L Peto; R Nanfuka; C Mufuka-Kapuya; P Kaleebu; D Pillay; V Robertson; D Yirrell; S Tugume; M Chirara; P Katundu; N Ndembi; F Lyagoba; D Dunn; R Goodall; A McCormick; A Medina Lara; S Foster; J Amurwon; B Nyanzi Wakholi; J Kigozi; L Muchabaiwa; M Muzambi; I Weller; A Babiker; S Bahendeka; M Bassett; A Chogo Wapakhabulo; J H Darbyshire; B Gazzard; C Gilks; H Grosskurth; J Hakim; A Latif; C Mapuchere; O Mugurungi; P Mugyenyi; C Burke; S Jones; C Newland; G Pearce; S Rahim; J Rooney; M Smith; W Snowden; J-M Steens; A Breckenridge; A McLaren; C Hill; J Matenga; A Pozniak; D Serwadda; T Peto; A Palfreeman; M Borok; E Katabira
Journal:  Lancet       Date:  2009-12-08       Impact factor: 79.321

10.  Differential drug resistance acquisition in HIV-1 of subtypes B and C.

Authors:  Esmeralda A J M Soares; André F A Santos; Thatiana M Sousa; Eduardo Sprinz; Ana M B Martinez; Jussara Silveira; Amilcar Tanuri; Marcelo A Soares
Journal:  PLoS One       Date:  2007-08-15       Impact factor: 3.240

View more
  18 in total

1.  Antiretroviral treatment failure, drug resistance, and subtype diversity in the only pediatric HIV clinic in Rhode Island.

Authors:  Tanya Rogo; Allison K DeLong; Philip Chan; Rami Kantor
Journal:  Clin Infect Dis       Date:  2015-01-30       Impact factor: 9.079

2.  HIV-1 second-line failure and drug resistance at high-level and low-level viremia in Western Kenya.

Authors:  Rami Kantor; Allison DeLong; Leeann Schreier; Marissa Reitsma; Emanuel Kemboi; Millicent Orido; Salome Obonge; Robert Boinett; Mary Rono; Wilfred Emonyi; Katie Brooks; Mia Coetzer; Nathan Buziba; Joseph Hogan; Lameck Diero
Journal:  AIDS       Date:  2018-11-13       Impact factor: 4.177

3.  Non-R5-tropic HIV-1 in subtype A1 and D infections were associated with lower pretherapy CD4+ cell count but not with PI/(N)NRTI therapy outcomes in Mbarara, Uganda.

Authors:  Guinevere Q Lee; Chris Lachowski; Eric Cai; Viviane D Lima; Yap Boum; Conrad Muzoora; Adrienne Rain Mocello; Peter W Hunt; Jeffrey N Martin; David R Bangsberg; P Richard Harrigan
Journal:  AIDS       Date:  2016-07-17       Impact factor: 4.177

4.  Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial.

Authors:  Rami Kantor; Laura Smeaton; Saran Vardhanabhuti; Sarah E Hudelson; Carol L Wallis; Srikanth Tripathy; Mariza G Morgado; Shanmugham Saravanan; Pachamuthu Balakrishnan; Marissa Reitsma; Stephen Hart; John W Mellors; Elias Halvas; Beatriz Grinsztejn; Mina C Hosseinipour; Johnstone Kumwenda; Alberto La Rosa; Umesh G Lalloo; Javier R Lama; Mohammed Rassool; Breno R Santos; Khuanchai Supparatpinyo; James Hakim; Timothy Flanigan; Nagalingeswaran Kumarasamy; Thomas B Campbell; Susan H Eshleman
Journal:  Clin Infect Dis       Date:  2015-02-13       Impact factor: 9.079

5.  Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda.

Authors:  Emmanuel Ndashimye; Mariano Avino; Fred Kyeyune; Immaculate Nankya; Richard M Gibson; Eva Nabulime; Art F Y Poon; Cissy Kityo; Peter Mugyenyi; Miguel E Quiñones-Mateu; Eric J Arts
Journal:  AIDS Res Hum Retroviruses       Date:  2018-02-26       Impact factor: 2.205

6.  High-level resistance to bictegravir and cabotegravir in subtype A- and D-infected HIV-1 patients failing raltegravir with multiple resistance mutations.

Authors:  Emmanuel Ndashimye; Yue Li; Paul S Reyes; Mariano Avino; Abayomi S Olabode; Cissy M Kityo; Fred Kyeyune; Immaculate Nankya; Miguel E Quiñones-Mateu; Stephen D Barr; Eric J Arts
Journal:  J Antimicrob Chemother       Date:  2021-10-11       Impact factor: 5.758

7.  Low-Frequency Drug Resistance in HIV-Infected Ugandans on Antiretroviral Treatment Is Associated with Regimen Failure.

Authors:  Fred Kyeyune; Richard M Gibson; Immaculate Nankya; Colin Venner; Samar Metha; Juliet Akao; Emmanuel Ndashimye; Cissy M Kityo; Robert A Salata; Peter Mugyenyi; Eric J Arts; Miguel E Quiñones-Mateu
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

8.  HIV diversity and drug resistance from plasma and non-plasma analytes in a large treatment programme in western Kenya.

Authors:  Rami Kantor; Allison DeLong; Maya Balamane; Leeann Schreier; Robert M Lloyd; Wilfred Injera; Lydia Kamle; Fidelis Mambo; Sarah Muyonga; David Katzenstein; Joseph Hogan; Nathan Buziba; Lameck Diero
Journal:  J Int AIDS Soc       Date:  2014-11-18       Impact factor: 5.396

9.  Infecting HIV-1 Subtype Predicts Disease Progression in Women of Sub-Saharan Africa.

Authors:  Colin M Venner; Immaculate Nankya; Fred Kyeyune; Korey Demers; Cynthia Kwok; Pai-Lien Chen; Sandra Rwambuya; Marshall Munjoma; Tsungai Chipato; Josaphat Byamugisha; Barbara Van Der Pol; Peter Mugyenyi; Robert A Salata; Charles S Morrison; Eric J Arts
Journal:  EBioMedicine       Date:  2016-10-12       Impact factor: 8.143

Review 10.  Addressing an HIV cure in LMIC.

Authors:  Sherazaan D Ismail; Joshua Pankrac; Emmanuel Ndashimye; Jessica L Prodger; Melissa-Rose Abrahams; Jamie F S Mann; Andrew D Redd; Eric J Arts
Journal:  Retrovirology       Date:  2021-08-03       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.